What PolTREG-T1D reveals about the future of cell therapy in autoimmune diseases
PolTREG advances its TREG cell therapy for type 1 diabetes toward EU approval. Learn what this milestone means for autoimmune disease treatment.
Pharma & Biotech
Pharma & Biotech
Why TIXiMED’s TIX100 data highlights a growing therapeutic gap after GLP-1 weight-loss treatment
TIXiMED reports preclinical data showing oral TIX100 may prevent weight regain after GLP-1 therapy. Discover what this could mean for obesity treatment.
Pharma & Biotech
Oragenics launches Phase IIa trial of ONP-002 as drug developers revisit traumatic brain injury therapies
Oragenics begins Phase IIa testing of ONP-002 for concussion. Discover how this trial could reshape drug development for traumatic brain injury.
Pharma & Biotech
Connect Biopharma advances rademikibart data as global competition grows in eczema biologics
Rademikibart Phase 3 eczema data will debut at AAD 2026. Discover what the trial could mean for IL-4 receptor biologics and global dermatology drug competition.
Pharma & Biotech
How Citius Oncology’s LYMPHIR program reflects a broader shift in immuno-oncology strategy
Citius Oncology reports early LYMPHIR plus pembrolizumab data in gynecologic cancers. Explore what the study reveals about the future of immuno-oncology strategies.
Pharma & Biotech
Novo Nordisk–Prothena coramitug program reaches key Phase 3 milestone in ATTR cardiomyopathy
Prothena earns a $50M milestone as Novo Nordisk advances coramitug in Phase 3 for ATTR cardiomyopathy. Discover what this means for amyloid therapies.
Pharma & Biotech
What the EU’s Elfabrio dosing update means for Fabry disease treatment burden
EU approves monthly Elfabrio dosing for Fabry disease. Discover how reduced infusion frequency could reshape enzyme therapy and treatment burden.
Pharma & Biotech
What Veru Inc.’s Phase 2b PLATEAU trial signals about the evolution of combination obesity drugs
Veru Inc. launches Phase 2b PLATEAU trial combining enobosarm with semaglutide for obesity. Discover what it means for next-generation weight-loss drugs.
Pharma & Biotech
Junshi Biosciences pushes subcutaneous PD-1 therapy as China’s oncology system strains
NMPA reviews subcutaneous toripalimab across 12 cancers. Discover how the delivery shift could reshape China’s immunotherapy infrastructure.
Pharma & Biotech
Can NovelMed Therapeutics challenge established PNH drugs with its Bb-targeting antibody Ruxoprubart?
NovelMed Therapeutics advances Ruxoprubart for paroxysmal nocturnal hemoglobinuria with Phase II data and a new subcutaneous trial. Discover what comes next.